Eli Lilly's (LLY) New Tirzepatide Results Suggest A Very Differentiated Product - Wolfe Research
Tweet Send to a Friend
Wolfe Research analyst Tim Anderson reiterated an Outperform rating and $235.00 price target on Eli Lilly (NYSE: LLY) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
